Abstract

Purpose:To evaluate the effect of intravitreal bevacizumab (IVB) injection on corneal biomechanical parameters as measured by the ocular response analyzer (ORA) and Corneal Visualization Scheimpflug Technology (CorVis).Methods:In this prospective pilot study, ORA and CorVis parameters were recorded before and after a three-month course of IVB injection therapy in 16 patients in the injected and the contralateral non-injected control eyes. The changes in the recorded parameters in each group and the differences between the two groups were evaluated and compared.Results:None of the changes in ORA parameters were statistically significant in the injected and non-injected groups before and three months after injection, except for corneal resistance factor (CRF) in injected eyes (paired t-test, P = 0.039). The differences in corneal hysteresis (CH) and CRF were not statistically significant between the two groups (P = 0.441 and 0.236, respectively), but significant differences were noted between corneal compensated IOP (IOPcc) and Goldmann-correlated IOP (IOPg) (P = 0.045 and 0.047, respectively). None of the changes in CorVis parameters were statistically significant in the groups before and at the end of study, except for the time of first corneal applanation (TAp1 ms) in the injected group (P = 0.040, paired t-test). Differences in TAp1, length of the second corneal applanation (LAp2 mm), velocity of the second corneal applanation (VAp2 m/s), intraocular pressure (IOP), and central corneal thickness (CCT) also showed borderline significance between the two groups.Conclusion:In this pilot study IVB injection could change CRF, IOPcc, IOPg, and TAP1 as measured by ORA and CorVis.

Highlights

  • It has been shown that the connective tissue growth factor (CTGF)/vascular endothelial growth factor (VEGF) ratio is a strong predictor of vitreoretinal fibrosis in PDR, and that intravitreal anti‐VEGF treatment causes increased fibrosis in eyes with PDR by increasing the level of CTGF.[1]

  • In two patients with diagnosis of branch retinal vein occlusion (BRVO), macular edema resolved with one intravitreal bevacizumab (IVB) injection and no further injection was administered

  • The aim of this pilot study was to investigate whether intravitreal bevacizumab injection affects the biomechanical parameters of the cornea

Read more

Summary

Introduction

It has been reported that CTGF is found in many tissues including cornea and sclera.[2] Increased proportional level of CTGF has been reported to result in stimulated matrix contraction by fibroblasts in cornea during wound healing.[3] The same effect in unwounded cornea may result in a change in corneal stiffness or biomechanics. This shift can have unpredictable effects on other ocular tissues such as the sclera and cornea. To the best of our knowledge, this is the first such study in this field

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.